A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We report four previously undescribed families with germline BRCA1‐associated protein‐1 gene (BAP1) mutations and expand the clinical phenotype of this tumor syndrome. The tumor spectrum in these families is predominantly uveal malignant melanoma (UMM), cutaneous malignant melanoma (CMM) and mesothelioma, as previously reported for germline BAP1 mutations. However, mutation carriers from three new families, and one previously reported family, developed basal cell carcinoma (BCC), thus suggesting inclusion of BCC in the phenotypic spectrum of the BAP1 tumor syndrome. This notion is supported by the finding of loss of BAP1 protein expression by immunochemistry in two BCCs from individuals with germline BAP1 mutations and no loss of BAP1 staining in 53 of sporadic BCCs consistent with somatic mutations and loss of heterozygosity of the gene in the BCCs occurring in mutation carriers. Lastly, we identify the first reported recurrent mutation in BAP1 (p.R60X), which occurred in three families from two different continents. In two of the families, the mutation was inherited from a common founder but it arose independently in the third family.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Cited by
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Nasu, M., Emi, M., Pastorino, S., Tanji, M., Powers, A., Luk, H., Baumann, F., Zhang, Y.-A., Gazdar, A., Kanodia, S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000471 · Cited by 326
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
Walpole, S., Pritchard, A. L., Cebulla, C. M., Pilarski, R., Stautberg, M., Davidorf, F. H., de la Fouchardière, A., Cabaret, O., Golmard, L., Stoppa-Lyonnet, D., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy171 · Cited by 253
Self-citationHow Asbestos and Other Fibers Cause Mesothelioma
Gaudino, G., Xue, J., & Yang, H. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.01 · Cited by 102
“Germline BAP1 mutations were associated with the increased risk of other tumors, like clear cell renal cell carcinoma (55,56), cutaneous melanoma, ocular melanoma (57), atypical Spitz tumors (46,58), basal cell carcinoma (59,60), peritoneal mesothelioma (61-63), cholangiocarcinoma (64), and meningioma (65,66).”
BackgroundCDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
Betti, M., Aspesi, A., Biasi, A., Casalone, E., Ferrante, D., Ogliara, P., Gironi, L. C., Giorgione, R., Farinelli, P., Grosso, F., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.011 · Cited by 78
Metadata
- Authors
- Wadt, K. A. W., Aoude, L. G., Johansson, P., Solinas, A., Pritchard, A., Crainic, O., Andersen, M. T., Kiilgaard, J. F., Heegaard, S., Sunde, L., Federspiel, B., Madore, J., Thompson, J. F., McCarthy, S. W., Goodwin, A., Tsao, H., Jönsson, G., Busam, K., Gupta, R., Trent, J. M., Gerdes, A. ‐., Brown, K. M., Scolyer, R. A., & Hayward, N. K.
- Venue
- Clinical Genetics
- Publisher
- Wiley
- Published
- 2014-11-06
- Volume
- 88
- Issue
- 3
- Pages
- 267-272
- ISSN
- 0009-9163 (ISSN-L)
- 1399-0004
- OpenAlex
- W1897441025
- Cited by
- 92
- References
- 1
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.